Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

Research output: Contribution to journalReviewpeer-review

  1. Calcitonin gene-related peptide - beyond migraine prophylaxis

    Research output: Contribution to journalComment/debateResearchpeer-review

  2. Ageing as a risk factor for neurodegenerative disease

    Research output: Contribution to journalReviewpeer-review

  3. Post-traumatic headache: epidemiology and pathophysiological insights

    Research output: Contribution to journalReviewpeer-review

  4. Does inflammation have a role in migraine?

    Research output: Contribution to journalReviewpeer-review

  5. CGRP as the target of new migraine therapies - successful translation from bench to clinic

    Research output: Contribution to journalReviewpeer-review

  1. Fibrinogen: A potential biomarker for predicting disease severity in multiple sclerosis

    Research output: Contribution to journalReviewpeer-review

  2. Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Aggressive multiple sclerosis (2): Treatment

    Research output: Contribution to journalReviewpeer-review

  • MAGNIMS Study Group
View graph of relations

Early evaluation of treatment response and prediction of disease evolution are key issues in the management of people with multiple sclerosis (MS). In the past 20 years, MRI has become the most useful paraclinical tool in both situations and is used clinically to assess the inflammatory component of the disease, particularly the presence and evolution of focal lesions - the pathological hallmark of MS. However, diffuse neurodegenerative processes that are at least partly independent of inflammatory mechanisms can develop early in people with MS and are closely related to disability. The effects of these neurodegenerative processes at a macroscopic level can be quantified by estimation of brain and spinal cord atrophy with MRI. MRI measurements of atrophy in MS have also been proposed as a complementary approach to lesion assessment to facilitate the prediction of clinical outcomes and to assess treatment responses. In this Consensus statement, the Magnetic Resonance Imaging in MS (MAGNIMS) study group critically review the application of brain and spinal cord atrophy in clinical practice in the management of MS, considering the role of atrophy measures in prognosis and treatment monitoring and the barriers to clinical use of these measures. On the basis of this review, the group makes consensus statements and recommendations for future research.

Original languageEnglish
JournalNature reviews. Neurology
Volume16
Issue number3
Pages (from-to)171-182
Number of pages12
ISSN1759-4758
DOIs
Publication statusPublished - Mar 2020

    Research areas

  • Atrophy/diagnostic imaging, Brain/diagnostic imaging, Consensus, Humans, Magnetic Resonance Imaging/methods, Multiple Sclerosis/diagnostic imaging, Practice Guidelines as Topic/standards, Prognosis, Randomized Controlled Trials as Topic/standards, Severity of Illness Index, Spinal Cord/diagnostic imaging

ID: 61519561